Epilepsy Clinical Trials 2024

Epilepsy Clinical Trials 2024

Epilepsy research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in epilepsy clinical trials today.

Trials for Lennox Gastaut Syndrome Patients

Trials for Temporal Lobe Epilepsy Patients

Phase 3 Trials

Trials With No Placebo

View More Related Trials

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to epilepsy

What are the top hospitals conducting epilepsy research?

When it comes to advancing the understanding and treatment of epilepsy, several hospitals are leading the charge with their innovative clinical trials. One such institution is the Northeast Regional Epilepsy Group in Hackensack, which currently has eight active epilepsy trials underway. Over the years, they have conducted a total of 19 trials since recording their first one in 2008. Similarly dedicated to exploring new possibilities for epilepsy treatment is the Mid-Atlantic Epilepsy and Sleep Center in Bethesda, with eight ongoing trials and an impressive history of 25 completed ones dating back to their initial trial in 2005.

In Boston, Massachusetts General Hospital stands at the forefront of epilepsy research as well. With eight active clinical trials focused on this condition and a notable record of conducting 19 previous studies since their first recorded trial in 2005, this esteemed hospital continues to make significant contributions towards improving outcomes for those living with epilepsy.

Further west, Mayo Clinic located in Rochester takes pride in its seven active epilepsy trials. Having initiated its pioneering investigation into this neurological disorder also during that time frame itself adds up achievements through twenty-eight accomplished experiments over time presents them as highly reputable medical establishment within these realms.

Last but not least we find ourselves at University of California San Francisco where six current epileptic-focused investigations are being carried out; despite having registered relatively late entry compared to other institutions -only just over a decade ago-, they too hold commendable track record holding twelve successful past probes from day one till now established themselves as worthy contenders contributing significantly towards enhancing our knowledge about Epilepsy

These esteemed hospitals not only provide hope for individuals affected by epilepsy but also serve as beacons lighting up paths toward improved treatments and potential cures. Through rigorous scientific inquiry and dedication from top researchers across different locations nationwide proves that collective efforts can indeed bring us closer to better management options making life more manageable for patients facing seizures related challenges- thus truly exemplifying power amid unity

Which are the best cities for epilepsy clinical trials?

When it comes to epilepsy clinical trials, several cities have emerged as leaders in research and development. New york City boasts 31 active trials, exploring treatments like Lorcaserin, Soticlestat, and Methylphenidate. Boston follows closely with 20 ongoing studies focused on innovative approaches such as Soticlestat, the STARSTIM device, and Vatiquinone. Miami also shows promising progress with 19 active trials investigating treatments like Lacosamide intravenous and Cenobamate. Rochester in Minnesota and Houston in Texas both have 18 active trials each studying various potential treatments for epilepsy patients. These cities offer individuals living with epilepsy opportunities to participate in cutting-edge clinical trials that pave the way for advancements in care for this condition.

Which are the top treatments for epilepsy being explored in clinical trials?

Exciting advancements are being made in the search for effective epilepsy treatments, with several options shining brightly in ongoing clinical trials. Among these top contenders is Speech Tasks, currently under investigation in two active trials dedicated to epilepsy research since its listing in 2015. Equally promising is brivaracetam, which has caught the attention of researchers with its involvement in 23 all-time epilepsy trials and two currently underway. Additionally, cenobamate and LP352 have each earned their place on this list through their participation in two active and all-time epilepsy studies. These groundbreaking treatments offer hope for a brighter future for individuals living with epilepsy worldwide.

What are the most recent clinical trials for epilepsy?

Promising advancements are being made in the realm of epilepsy treatment through recent clinical trials. One notable trial focuses on the use of methylphenidate, a medication commonly used for attention deficit hyperactivity disorder (ADHD), to manage epilepsy. This phase 4 study aims to assess its effectiveness and safety in individuals with epilepsy. Additionally, preliminary safety trials involving various phases (1 and 2) have been conducted to evaluate new approaches for managing this condition. Among them is LP352, an investigational drug being explored in a phase 2 trial with encouraging results thus far. Similarly, another phase 2 trial named Condition A has shown potential as an alternative therapy for people living with epilepsy. Furthermore, research into ketamine hydrochloride's efficacy in treating seizures continues to progress through a comprehensive phase 2 study. These ongoing efforts hold promise for improving the lives of those affected by epilepsy.

What epilepsy clinical trials were recently completed?

Recent advancements in epilepsy research have seen the completion of several noteworthy clinical trials. In April 2021, Neurocrine Biosciences completed a trial investigating NBI-827104 as a potential treatment option. Similarly, Children's Hospital Medical Center, Cincinnati concluded their trial on TAVT-18 (sirolimus) in September 2020. Additionally, Marinus Pharmaceuticals made significant strides with their Ganaxolone trial which was completed in May 2019. Finally, Seattle Children's Hospital wrapped up their ABI-009 study back in July 2018. These trials represent important milestones and offer hope for improved therapeutic options to help individuals living with epilepsy manage this challenging condition more effectively.